Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $24000.0.

  • Amylyx Pharmaceuticals' Capital Expenditures rose 22631.58% to $24000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $72000.0, marking a year-over-year decrease of 8539.55%. This contributed to the annual value of $157000.0 for FY2024, which is 8734.89% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Capital Expenditures of $24000.0 as of Q3 2025, which was up 22631.58% from $17000.0 recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Capital Expenditures high stood at $1.1 million for Q2 2022, and its period low was -$19000.0 during Q3 2024.
  • Its 5-year average for Capital Expenditures is $240500.0, with a median of $169500.0 in 2021.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 234285.71% in 2022, then crashed by 10532.21% in 2024.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Capital Expenditures stood at $186000.0 in 2021, then skyrocketed by 233.33% to $620000.0 in 2022, then tumbled by 42.58% to $356000.0 in 2023, then tumbled by 94.38% to $20000.0 in 2024, then rose by 20.0% to $24000.0 in 2025.
  • Its Capital Expenditures was $24000.0 in Q3 2025, compared to $17000.0 in Q2 2025 and $11000.0 in Q1 2025.